EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy

Faridoon, Jiyue Zheng, Tao Zhang, Shuilong Tong, Tao Liu, Jiuen Cui, Haojie Xu, Di Hu, Ying Shen, Yajing Yin, Danhua Zhao, Chensheng Tan und 7 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Faridoon und 18 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Design and Development, Suzhou Genhouse Bio Co., Ltd., No. 1 Xinze Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China. Hauptthemen laut MEDLINE: Methionine Adenosyltransferase, Drug Design, Brain, Enzyme Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic lethality has recently emerged as a new approach for the treatment of mutated genes that were previously considered undruggable. Targeting methionine adenosyltransferase 2A (MAT2A) in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene leads to synthetic lethality and thus has attracted significant interest in the field of precise anticancer drug development. Herein, we report the discovery of a series of novel MAT2A inhibitors featuring a pyrazolo[3,4-c]quinolin-4-one skeleton based on structure-based drug design. Further optimization led to compound 39, which has a high potency for inhibiting MAT2A and a remarkable selectivity for MTAP-deleted cancer cell lines. Compound 39 has a favorable pharmacokinetic profile with high plasma exposure and oral bioavailability, and it exhibits significant efficacy in xenograft MTAP-depleted models. Moreover, 39 demonstrates excellent brain exposure with a Kpuu of 0.64 in rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methionine AdenosyltransferaseDrug DesignBrainEnzyme InhibitorsHumansAnimalsStructure-Activity RelationshipRatsCell Line, TumorAntineoplastic AgentsMiceMaleRats, Sprague-DawleyXenograft Model Antitumor Assays

Substanzen

Methionine AdenosyltransferaseMAT2A protein, humanEnzyme InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Center for Drug Design and Development, Suzhou Genhouse Bio Co., Ltd., No. 1 Xinze Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China.

ORCID-Profile: Guiping Zhang

Zitieren

APA

Faridoon, Zheng, J., Zhang, T., Tong, S., Liu, T., Cui, J., Xu, H., Hu, D., Shen, Y., Yin, Y., Zhao, D., Tan, C., Dong, X., Chen, J., Ji, F., Tong, C., Li, J. J., Li, J., & Zhang, G. (2024). Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00552

Vancouver

Faridoon, Zheng J, Zhang T, Tong S, Liu T, Cui J, et al. Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00552

BibTeX
@article{Faridoon2024,
  author = {Faridoon and Zheng, Jiyue and Zhang, Tao and Tong, Shuilong and Liu, Tao and Cui, Jiuen and Xu, Haojie and Hu, Di and Shen, Ying and Yin, Yajing and Zhao, Danhua and Tan, Chensheng and Dong, Xue and Chen, Jiali and Ji, Feihong and Tong, Chenhua and Li, Jie Jack and Li, Jiapeng and Zhang, Guiping},
  title = {Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00552}
}
Kostenlos starten →